

CORPORATE SUPPORT

This Satellite Symposium is supported by an educational grant from:



REGISTRATION

This is a complimentary educational program and space is limited. No pre-registration is required.

SATELLITE ORGANIZER



4325 Alexander Drive
Alpharetta, Georgia
30022-3740, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

©2009 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

THE EMERGING ROLE OF THE INSULIN LIKE GROWTH FACTOR PATHWAY AS A TARGET IN LUNG CANCER


A SATELLITE SYMPOSIUM
HELD IN CONJUNCTION WITH THE
10TH EUROPEAN CONGRESS:
PERSPECTIVES IN LUNG CANCER



SATURDAY, 7 MARCH 2009
BRUSSELS, BELGIUM

12:15 - 13:15
LE PALACE BALLROOM
CROWNE PLAZA BRUSSELS CITY CENTRE

CHAIR
GIORGIO V. SCAGLIOTTI, MD, PHD
UNIVERSITY OF TORINO
ORBASSANO, ITALY



DEAR COLLEAGUES,

It is my pleasure on behalf of the faculty to invite you to a satellite symposium, sponsored by Pfizer Oncology, titled "The Emerging Role of the Insulin Like Growth Factor Pathway as a Target in Lung Cancer". The symposium will take place on Saturday, 7 March 2009 from 12:15 to 13:15.

In spite of recent advances, non-small cell lung cancer (NSCLC) remains an area of high unmet need. At this symposium, we will highlight the role played in cancer by a novel investigational target, the insulin-like growth factor 1 receptor (IGF-1R). Ongoing clinical studies are evaluating the potential of targeting IGF-1R in multiple tumor types, including NSCLC.

Please join me as Dr. Silvia Novello from the University of Torino (Italy) and Dr. Adrian Lee from Baylor College of Medicine (USA) discuss the scientific rationale of IGF-1R signaling in NSCLC. The objectives of this symposium are:

- (i) to raise the understanding of the role of IGF-1R in cancer in general and in NSCLC in particular.
- (ii) to review the evidence for potential cross-talk of the IGF-1R pathway with other signal transduction pathways.
- (iii) to share the preliminary pre-clinical and clinical data of agents targeting the IGF-1R pathway in NSCLC.
- (iv) to review ongoing trials with agents targeting the IGF-1R pathway in NSCLC.

I hope you will join me in Brussels to learn more about this novel investigational approach.



Sincerely yours,

Giorgio V. Scagliotti, MD, PhD
University of Torino, Orbassano, Italy

SCIENTIFIC AGENDA

12:15 CHAIR'S WELCOME AND INTRODUCTION

Giorgio V. Scagliotti, MD, PhD
University of Torino
Orbassano, Italy

12:20 THE ROLE OF THE IGF SIGNALING PATHWAY IN CANCER

Adrian V. Lee, PhD
Baylor College of Medicine
Houston, Texas
United States

12:45 EMERGING EVIDENCE OF THE IGF-1R AS A TARGET IN NSCLC

Silvia Novello, MD, PhD
University of Torino
Orbassano, Italy

13:10 QUESTIONS AND ANSWERS

13:15 ADJOURN

LOCATION

